-- STOCKS NEWS US-Large caps outperform as Dow leads Wall St gains
-- 
-- Mon Apr 28, 2014 10:26AM EDT
-- None



April 28 (Reuters) - Pending home sales for March notch their biggest rise in nearly two years at 3.4 percent over February's reading <USNCH=ECI><USNAR=ECI>.

March's pending home sales index clocks in at the highest since November, rebounding from a February level that was the lowest in more than two years. [ID:nW1N0K3004] Home builders' stocks are higher in the wake of the data: The Dow Jones U.S. Homebuilders Index <.DJUSHB> is up 2.6 percent on the day with nearly all of the move coming after the numbers hit at 10:00 a.m. The index is now 4.5 percent higher over the past four days, recovering further from a four-month low set last week. All seven index members are higher, lead by Lennar's <LEN.N> 3.5 percent rise. The S&P, Dow and Nasdaq all remain at least two-thirds of a percent higher on the day. The Nasdaq 100 <.NDX> just crossed over the 1 percent marker.  From earlier in the day:  10:00 - The Dow <.DJI> is outperforming in early trading after the opening bell, with IBM's <IBM.N> 2 percent gain leading the charge.  Pfizer's <PFE.N> also a top contributor to the index's 0.54 percent rise, with the drug maker's shares up 3 percent on news of its bold merger approach to AstraZeneca <AZN.L>. The S&P 500 <.SPX> is up around 0.33 percent and Nasdaq <.IXIC> is posting a 0.3 percent gain. Large-cap is generally outpacing small, with the S&P 100 <.OEXA> up 0.43 percent vs the Russell 2000's <.RUT> 0.18 percent rise.   09:00 - Monday's economic data calendar is light, with pending home sales for March from the National Association of Realtors the only indicator scheduled <ECONUSTODAY>. The index is expected to rise 1 percent from February's two-plus year low. The report is due at 10 a.m. ET and will keep the underperforming home building group in the spotlight. The SPDR S&P Homebuilders ETF <XHB.P> is down 6.7 percent year to date vs a gain of just under 1 percent for the S&P 500.08:54 - Pfizer <PFE.N> is among the top movers in the early going, up nearly 6 percent at $31.30 in premarket action vs. a $30.75 close.  The Dow component has pitched a takeover offer for British rival AstraZeneca Plc <AZN.L> worth nearly $100 billion and is weighing its next move in the approach after its first two bids were rejected. [ID:nL6N0NK194] AstraZeneca's U.S.-traded shares are up more than 16 percent at nearly $80 in premarket trading.  Pfizer's move follows a spate of deal activity across the health and pharma sector. Last week Zimmer <ZMH.N> agreed to buy Biomet for $13.4 billion, while over the weekend Reuters reported exclusively that Merck <MRK.N> is in talks to sell its consumer unit for nearly $14 billion. [ID:nL3N0NG3TQ][ID:nL6N0NI06U] In the deals-gone-sour department, Newmont Mining <NEM.N> is down close to 6 percent after merger talks with Canada's Barrick Gold <ABX.TO> were terminated. [ID:nL2N0NK0C6] For more on the morning's big movers ahead of the bell click [XHR/US]. On the wider market, index futures' gains are eroding, with the S&P e-minis <ESc1> now up just 3.75 points vs nearly 7 earlier.   08:32 - U.S. index futures are all higher Monday morning with more drug-sector M&A activity acting as the main driver. * S&P 500 e-minis <ESc1> are up 6 points, about 0.32 percent, with just under 145,000 contracts traded. * Nasdaq 100s <NDc1> are up 0.27 percent, or 9.75 points, though volume is miniscule at just 79 contracts.